Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 15, 2024 -- For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to a study published online Oct. 14 in JAMA Pediatrics.
Liya Kerem, M.D., and Joshua Stokar, M.D., from Hadassah University Medical Center in Israel, examined the incidence of suicidal ideation or attempts following initial prescription of GLP1-RA (study cohort) or a lifestyle intervention without GLP1-RA treatment (control cohort) in a retrospective propensity score-matched cohort. Participants were adolescents aged 12 to 18 years with a diagnosis of obesity and evidence of an antiobesity GLP1-RA prescription or lifestyle intervention without GLP1-RA treatment; after propensity score matching, 3,456 participants were included in each cohort.
The researchers found that the study cohort had a significantly lower risk for suicidal ideation or attempts during 12 months of follow-up (1.45 versus 2.26 percent; hazard ratio, 0.67) and a significantly higher rate of gastrointestinal symptoms, used as a positive control outcome (6.9 versus 5.4 percent; hazard ratio, 1.41). There was no difference between the groups in the rates of upper respiratory tract infection diagnoses, used as a negative control outcome.
"Future prospective studies should assess the association of GLP1-RA treatment with psychiatric outcomes in adolescents with obesity," the authors write.
One author disclosed ties to Novo Nordisk.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Depressive Symptoms Common for Women With Premature Ovarian Insufficiency
TUESDAY, July 22, 2025 -- The prevalence of depressive symptoms is high among women with premature ovarian insufficiency (POI), according to a study published online July 16...
Prevalence of Extremely Severe Obesity Increasing in Children
TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...
Insomnia Plays a Role in Quality of Life for Patients With ADHD
MONDAY, July 21, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) symptoms are associated with lower quality of life (QoL) in adults, and this association is only partially...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.